Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 30 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

20%

6 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (5)
Early P 1 (1)
P 1 (4)
P 2 (6)
P 3 (6)

Trial Status

Not Yet Recruiting17
Recruiting6
Completed4
Withdrawn3

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (30)

Showing 20 of 20 trials
NCT07480356Phase 3Not Yet RecruitingPrimary

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

NCT07342517Phase 3WithdrawnPrimary

A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

NCT07313891Phase 3Withdrawn

A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

NCT07464145Phase 3Not Yet RecruitingPrimary

A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer

NCT07441499Recruiting

Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

NCT07396038Not Yet RecruitingPrimary

INTRAOPERATIVE BLADDER INJURY ASSESSMENT IN TURBT USING BICEP

NCT07375641Not Yet Recruiting

The Impact of Age and Sex on Anticipated and Experienced Pain in First-Time Outpatient Flexible Cystoscopy

NCT07356791Phase 2Not Yet RecruitingPrimary

Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety

NCT07279792Phase 2CompletedPrimary

Implications of Post-Operative Irrigation Fluid's Osmolarity on the Recurrence of Non-Muscle Invasive Bladder Cancer Following Transurethral Resection

NCT07272603Early Phase 1Not Yet RecruitingPrimary

Bladder Perfusion of Plasma-Activated Saline for Bladder Cancer

NCT07073703Not ApplicableRecruitingPrimary

Effectiveness of a Personalized 6-month Programme on Frailty in Older Patients Treated for Bladder or Kidney Cancer.

NCT07207824Phase 3Not Yet RecruitingPrimary

DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC

NCT07203989Not ApplicableNot Yet Recruiting

The Effect of Video Calls With Family Members During Operating Room Waiting on Stress, Anxiety, and Surgical Fear in Patients Undergoing Transurethral Resection of Bladder Tumor

NCT07142200Phase 2Not Yet RecruitingPrimary

A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection

NCT07119996Phase 1Not Yet RecruitingPrimary

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

NCT07067749Phase 3RecruitingPrimary

Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer

NCT07080333Not ApplicableNot Yet RecruitingPrimary

MICROBIOTA AND BLADDER CANCER

NCT07064863Phase 1Not Yet Recruiting

A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.

NCT07053722Not Yet RecruitingPrimary

Observational Clinical Study of Patients With Muscle - Invasive Bladder Cancer Undergoing Bladder Preservation Therapy After Neoadjuvant Therapy

NCT07053735Phase 1Not Yet RecruitingPrimary

An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer

Scroll to load more

Research Network

Activity Timeline